6505-01-300-2115 ( K5086-11 , MA 89-288 )
NSN Information
| NSN | FSC | NIIN | Item Name | INC |
|---|---|---|---|---|
| 6505-01-300-2115 | 6505 | 013002115 | CEFTAZIDIME FOR INJECTION | 3734 |
NSN Features
| MRC | Parameter | Characteristics |
|---|---|---|
| AGXW | PHYSICAL FORM | POWDER |
| CSGS | ADMINISTRATION | INTRAMUSCULAR OR INTRAVENOUS |
| CQCT | PRIMARY CONTAINER TYPE | VIAL, MULTIPLE DOSE |
| AKJA | ACTIVE MEDICAMENT MEDICINAL STRENGTH | 6.000 GRAMS CEFTAZIDIME, ANHYDROUS EQUIVALENT |
| CRLK | PRIMARY CONTAINER CONTENT QUANTITY | 6.000 GRAMS OF ACTIVE INGREDIENT |
| FEAT | SPECIAL FEATURES | EACH VIAL CONTAINS CEFTAZIDIME PENTAHYDRATE EQUIVALENT TO 6 GRAMS OF CEFTAZIDIME,AND 118 MILLIGRAMS SODIUM CARBONATE PER GRAM OF CEFTAZIDIME; PHARMACY BULK PACK |
Manufacturing Part Numbers (SKUs)
| Part SKU | Cage | Status | RNVC | RNCC | SADC | DAC | RNAAC |
|---|---|---|---|---|---|---|---|
| K5086-11 | 60060 | A | 2 | 3 | 4 | ZZ | |
| MA 89-288 | 88009 | A | 2 | 3 | 4 | 54 |
Manufacturers
| Part SKU | Cage | Manufacturer | Type | Status |
|---|---|---|---|---|
| K5086-11 | 60060 | ABBOTT LABORATORIES INC. | A | A |
| MA 89-288 | 88009 | U S DEPT OF VETERANS AFFAIRS | A | A |
FLIS Identification
| PMIC | ADPE Code | CRITL Code | DEMIL Code | DEMIL INTG | NIIN Asgt | ESD | HMIC | ENAC | Schedule-B | INC |
|---|---|---|---|---|---|---|---|---|---|---|
| U | X | A | 1 | 05/11/1 | P | 3734 |
FLIS Management
| MOE | REC Rep Code | Mgmt Ctl | USC | Phrase Code | Phrase Statement |
|---|---|---|---|---|---|
| VA | V | K | U/I CONTAINS 6 GM |
Demilitarization Codes & Management
| DML | PMI | HMIC | ADP | CC | ESDC |
|---|---|---|---|---|---|
| A | U | P | X |
Miscellaneous Management
| MOE (S_A) | SOS | AAC | QUP | UI | SLC | CIIC | RC | MCC | SVC |
|---|---|---|---|---|---|---|---|---|---|
| VA | G36 | G | 0 | VI | M | U | V |
Management Control Army
| MATCAT 1 | MATCAT 2 | MATCAT 3 | MATCAT 4 5 | ARC |
|---|
Freight
| NMFC | NMFC SUB | UFC | HMC | LTL | LCL | WCC | TCC | SHC | ADC | ACC | ASH | NMF DESC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|